We build economic evaluations and decision models that help payers and health authorities decide which treatments to fund. Our projects span all MENA markets, and our models have been included in submissions to major governmental and private institutions in the region.
Leveraging our multidisciplinary expertise and state-of-the-art evidence synthesis and modeling methodologies, we deliver tailored, patient-centric solutions that drive value and impact for our partners.
Our Team of Specialists
CCHO’s team of experts ensures comprehensive and holistic HEOR support across the entire product lifecycle. Our expertise includes:
- Health economics
- Real-world evidence
- Patient-reported outcomes
- Epidemiology
- Biostatistics
- Advanced data analytics
- Health policy
- Physicians and pharmacists
Comprehensive Health Economic Services
We advise on selecting and applying the right methods for your research question. We also use methods that identify the patient groups who benefit most from a treatment, supporting personalized medicine.
Methodologies CCHO implements
Economic Modeling
Our economic modeling services are grounded in rigorous methodologies and extensive experience, ensuring robust and actionable insights for healthcare decision-making. Our capabilities include decision-analytic modeling, cost-effectiveness, budget impact analysis, and burden of disease studies.
These services are designed to evaluate the financial impacts of medical interventions, assess their value upon introduction, guide resource allocation decisions, and shape healthcare policy and practice across a broad spectrum of indications and complex disease areas. CCHO models have been included in submissions to major governmental and private institutions in the MENA region.
Burden of disease / cost of illness
- Disease incidence and prevalence
- Real-world outcomes
- Direct, indirect and intangible costs of disease
- Cost of treatment
- Health-related quality of life
- Healthcare resource utilization
Economic evaluation
- Cost-effectiveness analysis (CEA)
- Cost-minimization analysis (CMA)
- Cost-benefit analysis (CBA)
- Cost consequence
- Population health and budget impact analysis (BIA)
- Value-based pricing
- Local model adaptation
Decision-analytic modeling
- Decision trees
- Markov models
- Microsimulation models
Therapeutic Areas
- Hematology and oncology: breast and lung cancer, multiple myeloma, CML
- Rare diseases: myasthenia gravis, spinal muscular atrophy
- Neurology and immunology: multiple sclerosis, rheumatoid arthritis
- Infectious diseases: pneumococcal disease
- Cardiology: heart failure, ASCVD
- Dermatology: hidradenitis suppurativa, psoriasis
- Endocrinology: obesity, diabetes
- Gastroenterology: Crohn’s disease, ulcerative colitis
Recent Burden-of-Disease Studies
- A multi-country cost-of-illness model in a rare neuromuscular disease, completed and used to support regional submission dossiers.
- A single-country GCC model in chronic neuro-immunology, now in data collection.
Both capture quality of life with the EQ-5D-5L.
Publications
More than 50 publications and congress presentations across indications. See our publications
Every project is designed around your objectives.